PharmaVitae explores Bayer’s prescription pharmaceutical performance and outlook over 2019–29.
Following on from its M&A Outlook 2018 report, PharmaVitae highlights under the radar takeover targets that are potentially attractive to companies on the prowl for acquisitions.
PharmaVitae explores Takeda’s prescription pharmaceutical performance and outlook over 2019–29.
PharmaVitae explores Ono Pharmaceutical’s prescription pharmaceutical performance and outlook over 2019–29.
PharmaVitae explores Roche’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
PharmaVitae explores Biogen’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
PharmaVitae explores Incyte’s prescription pharmaceutical performance and outlook over 2019–29.
PharmaVitae explores Kyowa Kirin’s prescription pharmaceutical performance and outlook over 2019–29.
PharmaVitae explores Otsuka’s prescription pharmaceutical performance and outlook over 2019–29.
PharmaVitae explores Seattle Genetics’ prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
Tumbling over the patent cliff, many Big Pharma companies are being forced to find new strategies for sustaining sales growth, wherever possible minimizing the risk of generic competition.
Low-cost and skilled workforces in China and India have positioned both countries as increasingly important manufacturing hubs for pharmaceutical companies, as they seek to contain costs while retaining quality outsourcing partners.
Despite the apparent inevitability of the contract manufacturing organization (CMO) sector’s growth in China and India, a recent wave of scandals has put significant dents in the reputations of both countries as locations for foreign firms to manufacture drugs. Rising costs have also caused some firms to question whether using one of the region’s many CMOs is worth the risk.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!